Últimas noticias sobre Athira Pharma (NASDAQ:ATHA) Bolsa

Athira Pharma

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Athira Pharma Inc

Atha Energy Corp

Athabasca Minerals Inc

ATHABASCA OIL CORP by Athabasca Oil Corp.

Athabasca Oil Corp

Plains All American Pipeline, L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) reported&nbsp;fourth-quarter&nbsp;revenue of&nbsp;$12.402 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43556573/plains-all-american-reports-fourth-quarter-and-full-year-2024-results-provides-update-on-efficient" rel="noreferrer noopener">missing the consensus of&nbsp;$13.742 billion</a>.
Adjusted EPS was 42 cents, flat year-over-year,<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener"> beating the consensus of 40 cents</a>.
The adjusted EBITDA attributable to PAA fell 1% Y/Y to $729 million. The Crude Oil Segment Adjusted EBITDA rose 1% Y/Y to $569 million on higher tariff volumes, escalations, and contributions from acquisitions.
NGL segment Adjusted EBITDA fell&nbsp;9%&nbsp;YoY to&nbsp;$154 million&nbsp;due to lower weighted average frac spreads.
The company ended the year with a 3.0x leverage ratio. PAA&#8217;s operating cash flow for the year was&nbsp;$2.49 billion&nbsp;compared to&nbsp;$2.73 billion. Adjusted free cash flow was&nbsp;$1.25 billion in the year.
2025 Outlook: Plains All American sees adjusted EBITDA attributable to PAA of&nbsp;$2.80 billion &#8211; $2.95 billion, with <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">adjusted free cash flow of $1.15 billion</a>. This includes a reduction of around $580 million due to previously announced bolt-on transactions completed in the first quarter.
As announced earlier, the company disclosed distribution increase of $0.25 per unit payable February 14, 2025, representing a 20% aggregate increase in the annualized distribution vs.2024 levels, leading to new <a target="_blank" href="https://www.benzinga.com//node/42864671" rel="noreferrer noopener">annual distribution of $1.52 per unit.</a>
Plains All American expects the leverage ratio to be at or below the low end of the leverage target range of 3.25x to 3.75x.
The company targets growth capital of around $400 million and maintenance capital of about $240 million, net to PAA.
Willie Chiang, Chairman and CEO of Plains said, &#8220;We remain confident entering 2025, with strong operational momentum and focus on executing our efficient growth strategy. Our strong performance and positive outlook combined with the contribution from recent bolt-on acquisitions continues driving meaningful cash flow and underpins increasing returns to unitholders all while maintaining capital discipline and financial flexibility.&#8221;
Investors can gain exposure to the stock via&nbsp;InfraCap MLP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMZA#NYSE">AMZA</a>) and&nbsp;Alerian MLP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMLP#NYSE">AMLP</a>).
Price Action: PAA shares are up 0.35% at $20.08 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43553998/sp-500-gains-for-3rd-session-investor-sentiment-improves-but-greed-index-remains-in-fear-zone" target="_blank" rel="noreferrer noopener">S&amp;P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Large Cap

News

Guidance

AMLP

AMZA

Plains All American Q4: EPS Beat, Focus On Growth Strategy, Positive Outlook & More

Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Zimmer Biomet Holdingsto Hold

WIIM

AVTR

Avantor shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

Fortive shares are trading lower after the company reported worse-than-expected Q4 sales results. Additionally, the company issued FY25 and Q1 revenue guidance below estimates.

U.S. employment growth lost steam in January, with job growth coming in well below expectations and marking a significant slowdown <a href="https://www.benzinga.com/news/econ-s">from the previous month. </a>
Nonfarm payrolls rose by 143,000 in January 2025, marking a sharp slowdown from the upwardly revised 307,000 in December and missing economist expectations of 170,000, as tracked by TradingEconomics.
The softer-than-expected data hints at a gradual cooling in hiring momentum. The official jobs report also reveals a weaker-than-expected unemployment rate and hotter-than-expected wage growth, indicating mixed signals about the health of the U.S. labor market.
&#8220;In January, job gains occurred in health care, retail trade, and social assistance. Employment declined in the mining, quarrying, and oil and gas extraction industry,&#8221; the Bureau of Labor Statistics stated.
November&#8217;s total nonfarm payroll employment was revised higher by 49,000, increasing from 212,000 to 261,000, while December&#8217;s figure rose by 51,000, from 256,000 to 307,000.
Despite the weaker hiring pace, the unemployment rate surprisingly inched down from 4.1% to 4% in January, beating expectations of a stable reading.
Average hourly earnings, a key measure of wage inflation, spiked 0.5% month-over-month, topping expectations of 0.3% and marking the highest increase since January 2024. On an annual basis, wages increased 4.1%, up from 3.9% previously, and beating estimates of 3.8%. 
Beyond the headline numbers, Friday&#8217;s job market report also included the annual benchmark revision to the establishment survey and updated population controls in the household survey. 
The total nonfarm employment gain for the year ending March 2024 was revised down from 2,900,000 to 2,346,000.
<h3 class="wp-block-heading">Market Reaction</h3>
Financial markets showed little reactions to the jobs report, with U.S. equity futures holding flat as investors reassessed the Fed's policy outlook. 
The U.S. dollar index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), also remained steady.
On Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 0.4% higher.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43544975/banks-win-first-regulatory-relief-as-fed-softens-stress-test-rules-scraps-climate-risks-financial-stocks-hit-record-highs">Fed Eases Bank Stress Tests, Drops Climate Risks: Financial Stocks Hit Record Highs</a></li>
</ul>
Photo via Shutterstock.

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Markets

ETFs

PowerShares DB US Dollar Index Bullish Fund

US Economy Adds Fewer Than Expected Jobs In January, Unemployment Rate Slows, Wage Growth Spikes

Mettler-Toledo shares are trading higher following better-than-expected Q4 financial results. Also, the company raised its FY25 adjusted EPS guidance.

Legal

NTRB

Nutriband Receives Notice Of Allowance For Patent Application  18/369,241, "Abuse and Misuse Deterrent Transdermal Systems"; Covering Aversa Abuse Deterrent Technology.

PCTY

Paylocity shares are trading higher after the company reported better-than-expected Q2 revenue results and Needham raised its price target on the stock from $220 to $250.

Needham analyst Kyle Peterson maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and lowers the price target from $325 to $300.

Price Target

Needham Maintains Buy on Equifax, Lowers Price Target to $300

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

ENLV

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Accenture To Acquire Staufen AG; Terms Not Disclosed

Trading Ideas

SolarWinds Shares Halted On Circuit Breaker To The Upside, Stock Now Up 4.99%

ONTO

Onto Innovation shares are trading lower. The company reported Q4 financial results.

SolarWinds To Be Acquired By Turn/River Capital; Shareholders To Receive $18.50/Share With Total Enterprise Value Of $4.4B

Li Auto shares are trading higher after Macquarie upgraded the stock from Neutral to Outperform.

Needham analyst Tom Nikic reiterates Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy and maintains $84 price target.

Needham Reiterates Buy on Nike, Maintains $84 Price Target

DA Davidson analyst Tom White maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $190 to $205.

EXPE

DA Davidson Maintains Neutral on Expedia Group, Raises Price Target to $205

NBIX

Neurocrine Biosciences shares are trading lower after the company missed its Q4 revenue estimate when reporting financial results. Additionally, HC Wainwright & Co. and B of A Securities lowered their respective price targets on the stock.

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and recommended buying the same. &#8220;I think you've got a <a href="https://www.benzinga.com/quote/NEE/earnings">good one,&#8221; he added</a>.
On Jan. 24, NextEra Energy Inc posted in-line earnings for the fourth quarter and said it continues to expect adjusted EPS of $3.45-$3.70 for FY25.
<h3 class="wp-block-heading">Cramer&#8217;s Take On Tech Stocks</h3>
<ul>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) has missed the quarter too often, Cramer said. &#8220;If you want to be in that, you want to be in Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>).&#8221; The San Francisco-based company will release financial results for the fourth quarter after the closing bell on Wednesday, Feb. 12.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) is &#8220;up in a straight line, it's a parabolic move.&#8221; He noted that although it's a good company, but he can't recommend parabolic stocks. &#8220;Let that one come in,&#8221; he added. The San Jose, California-based company, on Feb. 4, posted better-than-expected earnings for its fourth quarter.</li>
</ul>
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has been bad for him, the Mad Money host said. &#8220;That last quarter was terrible, and, frankly, they were very smug on the call talking about how good it was, and that was a very ill-advised strategy that they adopted, and I don't like it.&#8221;
Supporting his view, Raymond James analyst Andrew Cooper, on Feb. 3, downgraded Danaher from Outperform to Market Perform.
IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is Jeffrey Gendell's [Chief Executive Officer for IES Holdings] company, Cramer said. &#8220;He is a, just an amazing man.&#8221;
As per the recent earnings report, IES, on Tuesday, reported quarterly earnings of $2.64 per share, up from $1.86 per share from the same period last year. The company reported $749.50 million in sales during the quarter, compared to $634.40 million the same period last year.
Cramer said Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is a &#8220;really great&#8221; company, but he doesn't want to recommend the stock. &#8220;It's the best house in a bad neighborhood, and we don't want to be in bad neighborhoods,&#8221; he added.
In the recent news, Schlumberger's OneSubsea joint venture on Tuesday entered an agreement with Vår Energi to deliver a subsea production systems work scope, aimed at supporting multiple upcoming oil and gas developments on the Norwegian Continental Shelf.
Price Action:
<ul>
<li>NextEra Energy shares gained 0.1% to settle at $69.27 on Thursday.</li>
<li>Fastly shares dipped 2.4% to close at $9.99 during the session.</li>
<li>Danaher shares fell 1% to settle at $210.01.</li>
<li>IES shares climbed 8.4% to close at $242.10 on Thursday.</li>
<li>SLB shares fell 1.9% to settle at $40.05.</li>
<li>A10 Networks shares fell 1.3% to close at $20.55 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43536198/top-2-industrials-stocks-that-are-ticking-portfolio-bombs">Top 2 Industrials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ATEN

FSLY

IESC

Jim Cramer Likes This Utilities Stock: 'I Think You've Got A Good One'

Needham analyst Mike Matson maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and lowers the price target from $112 to $108.

Needham Maintains Buy on Haemonetics, Lowers Price Target to $108

Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease will be presente...

Athira Pharma to present results from Phase 2/3 LIFT-AD trial

Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on&nbsp;TipRanks' Penny Stock Scre...

3 Penny Stocks to Watch Now, 11/5/24

"We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating dru...

Athira Pharma reports Q3 EPS (75c), consensus (71c)

Athira Pharma GAAP EPS of -$0.75 misses by $0.04

JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company's shares closed yesterday...

JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)

Athira Pharma, Inc. ( ($ATHA) ) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors...

Athira Pharma Reports Q3 2024 Financial Results

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dep...

Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline

Athena Gold upsizes private placement from C$1M to up to C$1.25M

Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of rese...

Athira Pharma to pay $4M to settle False Claims Act allegations

Alterity surges after mid-stage trial data for lead asset

AHNR

ATHA

TOVX

VSTE

Biotech

Press Releases

General

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

Health Care

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Comments

Athira Pharma

Noticias

Últimas noticias sobre Athira Pharma (NASDAQ:ATHA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL